North China Pharmaceutical Company.Ltd (SHA:600812)
China · Delayed Price · Currency is CNY 4.800
+0.040 (0.84%)
Jul 29, 2026, 3:00 PM CST
SHA:600812 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 8,236 | 9,488 | 8,870 | 9,780 | 10,981 | 20,452 | |
Market Cap Growth | -30.33% | 6.96% | -9.30% | -10.94% | -46.31% | 21.87% |
Enterprise Value | 19,472 | 20,188 | 19,926 | 20,598 | 20,895 | 30,116 |
Last Close Price | 4.80 | 5.49 | 5.11 | 5.62 | 6.31 | 11.64 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 50.98 | 51.83 | 69.85 | 1999.79 | - | 1092.06 |
Forward PE | - | 53.18 | 40.53 | 40.53 | 40.53 | 40.53 |
PS Ratio | 0.93 | 1.03 | 0.90 | 0.97 | 1.05 | 1.97 |
PB Ratio | 1.19 | 1.38 | 1.33 | 1.56 | 1.76 | 2.91 |
P/TBV Ratio | 3.21 | 3.81 | 3.37 | 2.93 | 3.01 | 4.32 |
P/FCF Ratio | 13.12 | 14.95 | 19.92 | 24.37 | 24.14 | 40.68 |
P/OCF Ratio | 7.03 | 8.06 | 7.21 | 9.55 | 10.93 | 19.47 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.21 | 2.18 | 2.02 | 2.04 | 1.99 | 2.90 |
EV/EBITDA Ratio | 12.63 | 13.31 | 13.73 | 16.15 | 15.51 | 24.60 |
EV/EBIT Ratio | 33.72 | 32.19 | 30.24 | 38.40 | 32.92 | 50.18 |
EV/FCF Ratio | 31.02 | 31.82 | 44.74 | 51.34 | 45.94 | 59.90 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 1.62 | 1.63 | 1.72 | 1.78 | 1.77 | 1.96 |
Debt / EBITDA Ratio | 7.29 | 7.16 | 7.52 | 7.88 | 7.81 | 10.57 |
Debt / FCF Ratio | 17.90 | 17.68 | 25.71 | 27.78 | 24.29 | 27.40 |
Net Debt / Equity Ratio | 1.42 | 1.41 | 1.47 | 1.62 | 1.50 | 1.21 |
Net Debt / EBITDA Ratio | 6.61 | 6.38 | 6.74 | 7.97 | 6.95 | 6.92 |
Net Debt / FCF Ratio | 15.70 | 15.25 | 21.98 | 25.32 | 20.59 | 16.85 |
Asset Turnover | 0.41 | 0.43 | 0.47 | 0.48 | 0.46 | 0.43 |
Inventory Turnover | 2.53 | 2.59 | 2.63 | 2.69 | 2.87 | 2.76 |
Quick Ratio | 0.49 | 0.45 | 0.50 | 0.49 | 0.49 | 0.70 |
Current Ratio | 0.72 | 0.66 | 0.75 | 0.78 | 0.72 | 0.89 |
Return on Equity (ROE) | 3.36% | 3.80% | 3.32% | 0.79% | -10.25% | 0.50% |
Return on Assets (ROA) | 1.66% | 1.83% | 1.94% | 1.59% | 1.72% | 1.54% |
Return on Invested Capital (ROIC) | 2.49% | 2.74% | 2.78% | 1.04% | 4.08% | 1.08% |
Return on Capital Employed (ROCE) | 5.80% | 7.00% | 6.30% | 5.00% | 7.20% | 5.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 1.96% | 1.93% | 1.43% | 0.05% | -6.28% | 0.09% |
FCF Yield | 7.62% | 6.69% | 5.02% | 4.10% | 4.14% | 2.46% |
Dividend Yield | 0.74% | 0.64% | 0.59% | 0.18% | - | 0.52% |
Payout Ratio | 257.31% | 225.53% | 369.37% | 10195.21% | - | 3987.68% |
Buyback Yield / Dilution | 0.92% | 0.31% | -5.27% | 4.92% | -0.70% | -4.96% |
Total Shareholder Return | 1.66% | 0.95% | -4.69% | 5.10% | -0.70% | -4.44% |